Susquehanna Fundamental Investments LLC Acquires Shares of 215,198 Nuvation Bio Inc. (NYSE:NUVB)

Susquehanna Fundamental Investments LLC bought a new position in Nuvation Bio Inc. (NYSE:NUVB - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 215,198 shares of the company's stock, valued at approximately $572,000. Susquehanna Fundamental Investments LLC owned 0.06% of Nuvation Bio as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. LPL Financial LLC increased its holdings in Nuvation Bio by 27.0% during the fourth quarter. LPL Financial LLC now owns 31,348 shares of the company's stock valued at $83,000 after buying an additional 6,673 shares during the period. Invesco Ltd. increased its holdings in shares of Nuvation Bio by 2.3% during the fourth quarter. Invesco Ltd. now owns 330,388 shares of the company's stock valued at $879,000 after acquiring an additional 7,344 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Nuvation Bio by 4.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 225,025 shares of the company's stock valued at $599,000 after purchasing an additional 9,758 shares during the last quarter. Forum Financial Management LP acquired a new stake in Nuvation Bio in the 4th quarter worth approximately $29,000. Finally, Cerity Partners LLC purchased a new stake in Nuvation Bio during the 4th quarter worth approximately $31,000. Institutional investors own 61.67% of the company's stock.

Insider Activity at Nuvation Bio

In other Nuvation Bio news, CEO David Hung bought 200,000 shares of the company's stock in a transaction that occurred on Friday, April 4th. The shares were purchased at an average price of $1.66 per share, with a total value of $332,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 58,481,054 shares of the company's stock, valued at $97,078,549.64. This represents a 0.34 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dongfang Liu sold 20,000 shares of Nuvation Bio stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $2.50, for a total value of $50,000.00. Following the sale, the insider now directly owns 12,000 shares of the company's stock, valued at $30,000. This trade represents a 62.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 29.93% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NUVB. Jones Trading started coverage on shares of Nuvation Bio in a report on Wednesday, March 12th. They issued a "buy" rating and a $10.00 price target for the company. HC Wainwright lowered their price target on Nuvation Bio from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Wedbush restated an "outperform" rating and set a $5.00 price objective on shares of Nuvation Bio in a research note on Thursday, March 27th. JMP Securities started coverage on Nuvation Bio in a research note on Wednesday, April 23rd. They issued a "market outperform" rating and a $6.00 target price on the stock. Finally, Citigroup assumed coverage on Nuvation Bio in a research report on Wednesday, April 23rd. They issued an "outperform" rating for the company. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $7.83.

Nuvation Bio Trading Up 1.0 %

NYSE NUVB traded up $0.02 on Friday, reaching $2.12. 1,636,050 shares of the company were exchanged, compared to its average volume of 2,175,017. Nuvation Bio Inc. has a fifty-two week low of $1.54 and a fifty-two week high of $3.97. The business's fifty day moving average price is $1.98 and its 200 day moving average price is $2.36. The stock has a market capitalization of $718.00 million, a P/E ratio of -0.98 and a beta of 1.42.

Nuvation Bio (NYSE:NUVB - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.16) EPS for the quarter, hitting analysts' consensus estimates of ($0.16). The firm had revenue of $3.08 million for the quarter, compared to analyst estimates of $0.42 million. Equities research analysts forecast that Nuvation Bio Inc. will post -0.36 earnings per share for the current year.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.